Michael Hitchcock

Michael Hitchcock

Michael (Mick) Hitchcock , Ph.D.

Adjunct Faculty
Developing drugs to treat infectious diseases

Summary

Professional Biography

  • 2009 - 2019: Senior Advisor, Gilead Sciences, Foster City, CA
  • 2016: Interim Head, Alliance Management, Gilead Sciences, Foster City, CA
  • 2011 - 2013: Interim Head Respiratory Therapeutic Area & Seattle Site Lead, Gilead Sciences, Seattle, WA
  • 2006 - 2009: VP, Project & Portfolio Management, Gilead Sciences, Foster City, CA
  • 2003 - 2006: VP, Medical Affairs, Gilead Sciences, Foster City, CA
  • 2002 - 2003: VP & Chief of Staff, R&D, Gilead Sciences, Foster City, CA
  • 2001 - 2002: VP, Discovery Team Management, Gilead Sciences, Foster City, CA
  • 1998 - 2001: VP, Project Management, Gilead Sciences, Foster City, CA
  • 1996 - 1998: VP, Strategic Planning, Gilead Sciences, Foster City, CA
  • 1994 - 1996: VP, Project Management, Gilead Sciences, Foster City, CA
  • 1993 - 1994: Director, Project Management, Gilead Sciences, Foster City, CA
  • 1990 - 1993: Director, Anti-Infective Project Planning & Management, Bristol-Myers Squibb, Pharmaceutical Research Division, Wallingford CT
  • 1987 - 1990: Assoc. Dir., Virology, Bristol-Myers, Pharmaceutical Research Division, Wallingford CT
  • 1986 - 1987: Assoc. Dir., Screening & Biochemical Research, Bristol-Myers, Pharmaceutical Research Division, Wallingford CT
  • 1982 - 1985: Senior Research Scientist, Dept. Microbiological Research, Bristol Laboratories, Syracuse, NY
  • 1980 - 1982: Senior Research Scientist, Dept. Experimental Chemotherapeutics, Bristol Laboratories, Syracuse, NY
  • 1979 - 1980: Visiting Fellow, Laboratory of Experimental Pathology, NIAMDD, National Institutes of Health, Bethesda, MD
  • 1976 - 1978: Research Associate, Georgetown University, Schools of Medicine & Dentistry, Department of Microbiology, Washington, DC

Research Interests

I have worked over the last 40 years to discover and develop drugs for diseases caused by bacteria (carbapenems, cephalosporins, aminoglycosides), viruses (HIV (triple combinations), hepatitis B (tenofovir prodrugs), hepatitis C (sofosbuvir based combinations), influenza (oseltamivir), CMV and herpes(cidofovir)) and fungi (various formulations of amphotericin B and azoles).

Education

  • 1976: Ph.D., Microbiology, Melbourne University
  • 1972: M.Sc., Biochemistry, University of Manchester Institute of Science & Technology
  • 1970: B.Sc., Biochemistry, University of Manchester Institute of Science & Technology